



Appendix 1

**This appendix was part of the submitted manuscript and has been peer reviewed.
It is posted as supplied by the authors.**

Appendix to: Sheridan SL, McCall BJ, Davis CA, et al. Acellular pertussis vaccine effectiveness for children during the 2009–2010 pertussis epidemic in Queensland. *Med J Aust* 2014; 200: 334–338. doi: 10.5694/mja13.11069.

Appendix 1: Summary of schedule changes for pertussis-containing vaccines in Queensland, 1999-2011⁸

Date	Description of schedule change
Pre-March 1999	Locally produced Diphtheria-tetanus-whole-cell pertussis vaccine (DTPw; Triple Antigen, Commonwealth Serum Laboratories [CSL], Australia), used for routine pertussis immunization at 2, 4, and 6-months, and 18-month and 4 to 5-year boosters
March 1999	Diphtheria-tetanus-acellular pertussis vaccine (DTPa; Infanrix, SmithKline Beecham Biologicals, Rixensart, Belgium) (3-component pertussis) and (DTPa; Tripacel, CSL/Pasteur Merieux Connaught, Toronto, Ontario, Canada) (5-component pertussis) introduced for 2, 4 and 6-month primary-course vaccines (replacing whole cell pertussis vaccine). DTPa continued to be provided for 18-month and 4 to 5-year booster vaccines
May 2000	Diphtheria-tetanus-acellular pertussis-hepatitis B vaccine (DTPaHepB; Infanrix-hepB, SmithKline Beecham Biologicals) (3-component pertussis) replaced DTPa for 2, 4 and 6-month vaccines
September 2003	18-month booster (DTPa) removed from schedule
January 2004	Diphtheria-tetanus-acellular pertussis adolescent/adult formulation booster (dTpa; Boostrix, GlaxoSmithKline Biologicals) (3-component pertussis) introduced for 15 to 17-year olds
November 2005	Diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine (DTPaIPV; Quadracel, Aventis Pasteur, Toronto, Ontario, Canada) (5-component pertussis) replaced DTPaHepB for 2, 4 and 6-month vaccines
July 2006	Diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine (DTPaIPV; Infanrix-IPV, GlaxoSmithKline Biologicals) (3-component pertussis) replaced DTPaIPV (5-component) for 2, 4 and 6-month vaccines
March 2008	Diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis vaccine-Haemophilus influenzae type b (Hib) (DTPa-hepB-IPV-Hib; Infanrix-hexa, GlaxoSmithKline Biologicals) (3-component pertussis) replaced DTPaIPV (3-component) for 2, 4 and 6-month vaccines
September 2010	Recommendation for 2-month primary-course DTPa-containing vaccine to be given at 6-weeks of age in response to pertussis epidemic